Edition:
United States

Aerie Pharmaceuticals Inc (AERI.OQ)

AERI.OQ on NASDAQ Stock Exchange Global Market

51.25USD
23 May 2018
Change (% chg)

-- (--)
Prev Close
$51.25
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
108,723
52-wk High
$66.55
52-wk Low
$39.65

Select another date:

Tue, May 15 2018

BRIEF-Aerie Pharmaceuticals Submits NDA To U.S. FDA For Roclatantm

* AERIE PHARMACEUTICALS SUBMITS NEW DRUG APPLICATION TO U.S. FOOD AND DRUG ADMINISTRATION FOR ROCLATANTM (NETARSUDIL/LATANOPROST OPHTHALMIC SOLUTION) 0.02%/0.005%

BRIEF-Aerie Pharmaceuticals Reports Q1 Adjusted Loss Per Share $0.83

* AERIE PHARMACEUTICALS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

BRIEF-Aerie Pharmaceuticals Announces U.S. Launch Of Rhopressa 0.02%

* AERIE PHARMACEUTICALS ANNOUNCES U.S. LAUNCH OF RHOPRESSA® (NETARSUDIL OPHTHALMIC SOLUTION) 0.02%

BRIEF-Aerie Pharmaceuticals CEO Vicente Anido's 2017 Total Compensation Was $10.06 Million

* AERIE PHARMACEUTICALS INC SAYS CEO VICENTE ANIDO'S 2017 TOTAL COMPENSATION WAS $10.06 MILLION – SEC FILING Source text for Eikon: (http://bit.ly/2Kn2hS6) Further company coverage:

BRIEF-Aerie Pharmaceuticals Reports Q4 Adjusted Loss Per Share $1.38

* AERIE PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE AND 2018 GUIDANCE

BRIEF-Aerie Pharmaceuticals Announces Pricing Of Public Offering Of Common Stock

* AERIE PHARMACEUTICALS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK

BRIEF-Aerie Pharmaceuticals Commences Public Offering Of $75 Million Of Common Stock

* AERIE PHARMACEUTICALS ANNOUNCES PUBLIC OFFERING OF COMMON STOCK

BRIEF-Aerie Pharmaceuticals Appoints Julia Williams As Director Of Medical Affairs

* AERIE PHARMACEUTICALS ANNOUNCES APPOINTMENT OF JULIA WILLIAMS AS DIRECTOR OF MEDICAL AFFAIRS Source text for Eikon: Further company coverage:

BRIEF-Aerie Pharma Enters Controlled Equity Offering Sales Agreement With Cantor Fitzgerald

* AERIE PHARMA SAYS ON DEC 19, CO ENTERED INTO CONTROLLED EQUITY OFFERING(SM)SALES AGREEMENT WITH CANTOR FITZGERALD - SEC FILING

UPDATE 2-Aerie's glaucoma treatment gets early FDA approval

Dec 18 Aerie Pharmaceuticals Inc said on Monday the U.S. Food and Drug Administration (FDA) approved its eyedrop, Rhopressa, as a treatment for glaucoma, two months ahead of the expected date.

Select another date: